Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA grants breakthrough therapy designation to Pfizer’s elranatamab for multiple myeloma 

By Brian Buntz | November 3, 2022

PfizerThe investigational bispecfic antibody elranatamab has won breakthrough therapy designation from the FDA for relapsed or refractory multiple myeloma (RRMM).

Also known as PF-06863135, erlanatamab is a B-cell maturation antigen (BCMA)-targeted T-cell redirecting immunotherapy. BCMA is highly expressed on the surface of multiple myeloma (MM) cells. Elranatamab is also designed to target the CD3 receptor on the surface of T-cells to destroy myeloma cells.

Pfizer is developing elranatamab for subcutaneous use, which it believes could reduce adverse effects from the drug candidate such as cytokine release syndrome (CRS) while also offering improved convenience over IV infusions.

FDA previously granted fast track designation to the drug candidate to accelerate its rapid development and regulatory review.

To date, Pfizer has won twelve breakthrough therapy designations from FDA in oncology.

FDA’s decision to grant breakthrough therapy designation to elranatamab rests on six-month follow-up data from cohort A (n=123) of the open-label Phase 2 MagnetisMM-3 study.

In that study, RRMM patients received a 76 mg dose of elranatamab monotherapy each week with a two-step-up priming dose regimen in the first week.

The main endpoint of the trial was objective response rate.

To date, the drug candidate had a manageable safety profile at 6.8 months. Cytokine release syndrome was the most common adverse event, affecting 57.9% of participants. The majority of cases were either Grade 1 or 2.

The drug candidate had an overall response rate (ORR) of 61.0%. Patients who were responders had a 90.4% probability of maintaining a response at six or more months.

Pfizer plans on sharing additional information related to the drug candidate at the 2022 ASH Annual Meeting and Exposition, scheduled for December 10 to 13 in New Orleans, Louisiana.

Positive data related to elranatamab were published last year in Blood.

PFE shares were down about 1% to $46.57.

Last year, Pfizer accused a former employee in the U.S. District Court for the Southern District of California of stealing documents related to the avelumab and elranatamab monoclonal antibodies.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: elranatamab, Pfizer
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

AP Biosciences charts course for safer CD137 bispecifics with its T-cube platform
Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T
Why smaller, simpler molecular glues are gaining attention in drug discovery
Technology background. Big data concept. Binary computer code. Vector illustration.
COTA Healthcare announces AI milestone in real-world oncology data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE